JPRN-jRCT2041210123进行中（未招募）2 期
A prospective, open label, multicenter, single arm, Phase 2 study of 177Lu-PSMA-617 in the treatment of participants with progressive PSMA-positive metastatic castrationresistant prostate cancer(mCRPC) in Japan
Kazuyuki Suzuki0 个研究点目标入组 28 人开始时间: 2021年12月26日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •ECOG performance status:
- •1. Post-taxane population only: 0 to 2.
- •2. Pre-taxane population only: 0 to 1.
- •- Participants must have a previous histological, pathological, and/or cytological confirmation of prostate cancer.
- •- Participants must have a positive 68Ga-PSMA-11 PET/CT scan, as determined by the sponsor's central reader, before the enrollment to 177Lu-PSMA-617 treatment period.
- •- Participants must have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L).
- •- Post-taxane population only: Participants must have received at least one ARDT (for example enzalutamide, abiraterone, apalutamide, or darolutamide, etc.) in either the hormone-sensitive/castrate-resistant or non-metastatic/metastatic prostate cancer setting.
- •- Pre-taxane population only: Participants must have received one prior approved ARDT (for example, abiraterone, enzalutamide, darolutamide, or apalutamide, etc.) and have documented progression on therapy and be a candidate for additional treatment with an alternate ARDT as assessed by the treating physician
- •- Post-taxane population only: Participants must have been previously treated with at least 1, but no more than 2 prior taxane regimens. A taxane regimen is defined as a minimum exposure of 2 cycles of a taxane. If a participant has received only 1 taxane regimen, the participant is eligible if :
- •a. The participant's physician deems him unsuitable to receive a second taxane regimen (e.g., frailty assessed by geriatric or health status evaluation or intolerance, etc.).
- •- Participants must have progressive mCRPC. Documented progressive mCRPC will be based on at least 1 of the following criteria:
- •1. Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
- •2. Soft-tissue progression defined as an increase >=20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions.
- •3. Progression of bone disease: evaluable disease or new bone lesions(s) by bone scan (PCWG3 criteria, Scher et al 2016).
- •- Participants must have at least one measurable lesion per PCWG3-modified RECIST v1.1 on CT or MRI.
排除标准
- •- Previous treatment with any of the following within 6 months of the enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted therapy is not allowed.
- •- Post-taxane population: Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies], ARDT is not included) within 28 days prior to day of the enrollment.
- •- Pre-taxane population: Prior treatment with cytotoxic chemotherapy for castration resistant or castrate sensitive prostate cancer (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy [including monoclonal antibodies]) [Note: Taxane exposure (maximum 6 cycles) in the adjuvant or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy]
- •- Known hypersensitivity to the components of 177Lu-PSMA-617, 68Ga-PSMA-11 or excipients or to drugs of similar classes.
- •- Other concurrent cytotoxic chemotherapy, immunotherapy, radioligand therapy, PARP inhibitors, or AKT inhibitors or investigational therapy.
- •- Participants with a history of CNS metastases must have received therapy (surgery, radiotherapy, gamma knife) and be neurologically stable, asymptomatic, and not receiving corticosteroids for the purposes of maintaining neurologic integrity.
- •- Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression.
研究者
相似试验
招募中
不适用
utrition supplement for tube feeding assessed in hospitalized (ICU Stay) patientsCTRI/2022/12/047818Dr Reddys Laboratories
招募中
Unknown
A prospective study to evaluate the safety and the efficacy of blood pressure reduction of Laparoscopic RDN in patients with resistant hypertensioDiseases of the circulatory systemKCT0009209DeepQure10
已完成
3 期
Trial to evaluate 3mg dose of Covid Vaccine of Cadila healthcare LimitedCTRI/2021/10/037137Cadila Healthcare Limited3,000
已完成
4 期
A prospective, multicentre, open-label, single armobservational study of Concor® treatment in Asian patientswith Essential HypertensioCTRI/2010/091/002813Merck Pte Ltd3 International Business Park #02-01Nordic European CentreSingapore 6099271,000
进行中（未招募）
4 期
A study to evaluate the safety and efficacy of Nutricharge Glycem Tablet administered with Nutricharge Glycem Prodiet in Pre-diabetic subjectsCTRI/2017/10/010007Trophic Wellness Private Limited